Skip to main content
Erschienen in: Pathology & Oncology Research 4/2010

01.12.2010

Increased Expression of Prohibitin and its Relationship with Poor Prognosis in Esophageal Squamous Cell Carcinoma

verfasst von: Hong-Zheng Ren, Jin-Sheng Wang, Peng Wang, Guo-qing Pan, Ji-Fang Wen, Hua Fu, Xu-zheng Shan

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Prohibitin, a potential tumor suppressor, has been shown to be an anti- proliferative protein, a regulator of cell-cycle progression and in apoptosis. Recently, it was found to be over-expressed in breast cancer and gastric cancer, and it has been suggested as a biomarker in those diseases. To clarify the role and the prognostic significance of prohibitin expression in esophageal squamous cell carcinoma (ESCC), we analyzed the expression in ESCC and their corresponding nonneoplastic epithelia tissues by immunohistochemistry(IHC), Western blotting and real-time quantitative reverse transcription polymerase chain reaction(QRT-PCR).The relationship between prohibitin expression and clinicopathological variables was examined by statistical analysis. The findings suggested the up-regulation of prohibitin play an important role in the carcinogenesis of ESCC. The over-expression of prihibitin was significantly correlated with the depth of tumor, lymph node metastasis, distant metastasis, lymphatic invasion and vascular invasion of ESCC. These results suggested that prohibitin(+), lymph node metastasis and distant metastasis could be the independent risk factors for worse prognosis in ESCC patients.
Literatur
1.
Zurück zum Zitat Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer 99(6):860–868CrossRefPubMed Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer 99(6):860–868CrossRefPubMed
2.
Zurück zum Zitat Stoner GD, Gupta A (2001) Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 22(11):1737–1746CrossRefPubMed Stoner GD, Gupta A (2001) Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 22(11):1737–1746CrossRefPubMed
3.
Zurück zum Zitat Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108CrossRefPubMed
4.
Zurück zum Zitat Piper PW, Bringloe D (2002) Loss of prohibitins, though it shortens the replicative life span of yeast cells undergoing division, does not shorten the chronological life span of G0-arrested cells. Mech Ageing Dev 123(4):287–295CrossRefPubMed Piper PW, Bringloe D (2002) Loss of prohibitins, though it shortens the replicative life span of yeast cells undergoing division, does not shorten the chronological life span of G0-arrested cells. Mech Ageing Dev 123(4):287–295CrossRefPubMed
5.
Zurück zum Zitat Dell’Orco RT, McClung JK, Jupe ER, Liu XT (1996) Prohibitin and the senescent phenotype. Exp Gerontol 31(1–2):245–252CrossRefPubMed Dell’Orco RT, McClung JK, Jupe ER, Liu XT (1996) Prohibitin and the senescent phenotype. Exp Gerontol 31(1–2):245–252CrossRefPubMed
6.
Zurück zum Zitat Jupe ER, Liu XT, Kiehlbauch JL, McClung JK, Dell’Orco RT (1996) The 39 untranslated region of prohibitin and cellular immortalization. Exp Cell Res 224(1):128–135CrossRefPubMed Jupe ER, Liu XT, Kiehlbauch JL, McClung JK, Dell’Orco RT (1996) The 39 untranslated region of prohibitin and cellular immortalization. Exp Cell Res 224(1):128–135CrossRefPubMed
7.
Zurück zum Zitat Kang X, Zhang L, Sun J et al (2008) Prohibitin: a potential biomarker for tissue-based detection of gastric cancer. J Gastroenterol 43(8):618–625CrossRefPubMed Kang X, Zhang L, Sun J et al (2008) Prohibitin: a potential biomarker for tissue-based detection of gastric cancer. J Gastroenterol 43(8):618–625CrossRefPubMed
8.
Zurück zum Zitat Dell’Orco RT, Jupe ER, Manjeshwar S et al (1997) Prohibitin: a new biomarker for breast tumors. Breast J 3:85–89CrossRef Dell’Orco RT, Jupe ER, Manjeshwar S et al (1997) Prohibitin: a new biomarker for breast tumors. Breast J 3:85–89CrossRef
9.
Zurück zum Zitat Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer-Verlag, New York Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging manual, 6th edn. Springer-Verlag, New York
10.
Zurück zum Zitat Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847CrossRefPubMed Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847CrossRefPubMed
11.
Zurück zum Zitat Gastl G, Spizzo G, Obrist P, Dünser M, Mikuz G (2000) Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356(9246):1981–1982CrossRefPubMed Gastl G, Spizzo G, Obrist P, Dünser M, Mikuz G (2000) Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356(9246):1981–1982CrossRefPubMed
12.
Zurück zum Zitat Pancione M, Forte N, Sabatino L et al (2009) Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum Pathol 40(5):714–725CrossRefPubMed Pancione M, Forte N, Sabatino L et al (2009) Reduced beta-catenin and peroxisome proliferator-activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum Pathol 40(5):714–725CrossRefPubMed
13.
Zurück zum Zitat Allen JW, Richardson JD, Edwards MJ (1997) Squamous cell carcinoma of the esophagus: a review and update. Surg Oncol 6(4):193–200CrossRefPubMed Allen JW, Richardson JD, Edwards MJ (1997) Squamous cell carcinoma of the esophagus: a review and update. Surg Oncol 6(4):193–200CrossRefPubMed
14.
Zurück zum Zitat Nijtmans LG, de Jong L, Artal Sanz M et al (2000) Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J 19(11):2444–2451CrossRefPubMed Nijtmans LG, de Jong L, Artal Sanz M et al (2000) Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J 19(11):2444–2451CrossRefPubMed
15.
Zurück zum Zitat Coates PJ, Nenutil R, McGregor A et al (2001) Mammalian PHB proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res 265(2):262–273CrossRefPubMed Coates PJ, Nenutil R, McGregor A et al (2001) Mammalian PHB proteins respond to mitochondrial stress and decrease during cellular senescence. Exp Cell Res 265(2):262–273CrossRefPubMed
16.
Zurück zum Zitat McClung JK, Jupe ER, Liu XT, Dell’Orco RT (1995) Prohibitin: potential role in senescence, development, and tumor suppression. Exp Gerontol 30(2):99–124CrossRefPubMed McClung JK, Jupe ER, Liu XT, Dell’Orco RT (1995) Prohibitin: potential role in senescence, development, and tumor suppression. Exp Gerontol 30(2):99–124CrossRefPubMed
17.
Zurück zum Zitat Ikonen E, Fiedler K, Parton RG, Simons K (1995) Prohibitin, an antiproliferative protein, is localized to mitochondria. FEBS Lett 358(3):273–277CrossRefPubMed Ikonen E, Fiedler K, Parton RG, Simons K (1995) Prohibitin, an antiproliferative protein, is localized to mitochondria. FEBS Lett 358(3):273–277CrossRefPubMed
18.
Zurück zum Zitat Wang S, Nath N, Adlam M, Chellappan S (1999) Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 18(23):3501–3510CrossRefPubMed Wang S, Nath N, Adlam M, Chellappan S (1999) Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 18(23):3501–3510CrossRefPubMed
19.
Zurück zum Zitat Wang KJ, Wang RT, Zhang JZ (2004) Identification of tumor markers using two- dimensional electrophoresis in gastric carcinoma. World J Gastroenterol 10(15):2179–2183PubMed Wang KJ, Wang RT, Zhang JZ (2004) Identification of tumor markers using two- dimensional electrophoresis in gastric carcinoma. World J Gastroenterol 10(15):2179–2183PubMed
20.
Zurück zum Zitat Ummanni R, Junker H, Zimmermann U et al (2008) Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett 266(2):171–185CrossRefPubMed Ummanni R, Junker H, Zimmermann U et al (2008) Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett 266(2):171–185CrossRefPubMed
21.
Zurück zum Zitat Asamoto M, Cohen SM (1994) Prohibitin gene is overexpressed but not mutated in rat bladder carcinomas and cell lines. Cancer Lett 83(1–2):201–207CrossRefPubMed Asamoto M, Cohen SM (1994) Prohibitin gene is overexpressed but not mutated in rat bladder carcinomas and cell lines. Cancer Lett 83(1–2):201–207CrossRefPubMed
22.
Zurück zum Zitat Jupe ER, Liu XT, Kiehlbauch JL, McClung JK, Dell’Orco RT (1996) Prohibitin in breast cancer cell lines: loss of antiproliferative activity is linked to 3′untranslated region mutations. Cell Growth Differ 7(7):871–878PubMed Jupe ER, Liu XT, Kiehlbauch JL, McClung JK, Dell’Orco RT (1996) Prohibitin in breast cancer cell lines: loss of antiproliferative activity is linked to 3′untranslated region mutations. Cell Growth Differ 7(7):871–878PubMed
23.
Zurück zum Zitat Pickens A, Orringer MB (2003) Geographical distribution and racial disparsity in esophageal cancer. Ann Thorac Surg 76(4):S1367–1369CrossRefPubMed Pickens A, Orringer MB (2003) Geographical distribution and racial disparsity in esophageal cancer. Ann Thorac Surg 76(4):S1367–1369CrossRefPubMed
Metadaten
Titel
Increased Expression of Prohibitin and its Relationship with Poor Prognosis in Esophageal Squamous Cell Carcinoma
verfasst von
Hong-Zheng Ren
Jin-Sheng Wang
Peng Wang
Guo-qing Pan
Ji-Fang Wen
Hua Fu
Xu-zheng Shan
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2010
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-009-9242-1

Weitere Artikel der Ausgabe 4/2010

Pathology & Oncology Research 4/2010 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.